Skip to main content

Interim Results from a Phase 2 Pivotal Study (DALY II USA) of Tandem CD20-CD19-Directed Non-Cryopreserved CAR-T Cells - Zamtocabtagene Autoleucel (Zamto-Cel) in Patients with Relapsed/Refractory Diffuse Large B Cell Lymphoma

Publication ,  Conference
Shah, NN; Maziarz, RT; Jacobson, CA; Johnston, PB; Abhyankar, S; Isufi, I; Perales, MA; Ghosh, M; Ulrickson, M; Rosenthal, AC; Munoz, JL ...
Published in: Blood
November 5, 2024

Duke Scholars

Published In

Blood

DOI

EISSN

1528-0020

ISSN

0006-4971

Publication Date

November 5, 2024

Volume

144

Issue

Supplement 1

Start / End Page

68 / 68

Publisher

American Society of Hematology

Related Subject Headings

  • Immunology
  • 3213 Paediatrics
  • 3201 Cardiovascular medicine and haematology
  • 3101 Biochemistry and cell biology
  • 1114 Paediatrics and Reproductive Medicine
  • 1103 Clinical Sciences
  • 1102 Cardiorespiratory Medicine and Haematology
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Shah, N. N., Maziarz, R. T., Jacobson, C. A., Johnston, P. B., Abhyankar, S., Isufi, I., … Miklos, D. B. (2024). Interim Results from a Phase 2 Pivotal Study (DALY II USA) of Tandem CD20-CD19-Directed Non-Cryopreserved CAR-T Cells - Zamtocabtagene Autoleucel (Zamto-Cel) in Patients with Relapsed/Refractory Diffuse Large B Cell Lymphoma. In Blood (Vol. 144, pp. 68–68). American Society of Hematology. https://doi.org/10.1182/blood-2024-208539
Shah, Nirav N., Richard T. Maziarz, Caron A. Jacobson, Patrick B. Johnston, Sunil Abhyankar, Iris Isufi, Miguel Angel Perales, et al. “Interim Results from a Phase 2 Pivotal Study (DALY II USA) of Tandem CD20-CD19-Directed Non-Cryopreserved CAR-T Cells - Zamtocabtagene Autoleucel (Zamto-Cel) in Patients with Relapsed/Refractory Diffuse Large B Cell Lymphoma.” In Blood, 144:68–68. American Society of Hematology, 2024. https://doi.org/10.1182/blood-2024-208539.
Shah, Nirav N., et al. “Interim Results from a Phase 2 Pivotal Study (DALY II USA) of Tandem CD20-CD19-Directed Non-Cryopreserved CAR-T Cells - Zamtocabtagene Autoleucel (Zamto-Cel) in Patients with Relapsed/Refractory Diffuse Large B Cell Lymphoma.” Blood, vol. 144, no. Supplement 1, American Society of Hematology, 2024, pp. 68–68. Crossref, doi:10.1182/blood-2024-208539.
Shah NN, Maziarz RT, Jacobson CA, Johnston PB, Abhyankar S, Isufi I, Perales MA, Ghosh M, Ulrickson M, Rosenthal AC, Munoz JL, Hardy NM, Rapoport AP, Karmali R, Awan FT, McKinney MS, Horwitz M, Lunning M, Denlinger N, Ancukiewicz M, Nallewar M, Coleman KC, Eromosele E, Kaleta R, Theruvath J, Wijatyk A, Miklos DB. Interim Results from a Phase 2 Pivotal Study (DALY II USA) of Tandem CD20-CD19-Directed Non-Cryopreserved CAR-T Cells - Zamtocabtagene Autoleucel (Zamto-Cel) in Patients with Relapsed/Refractory Diffuse Large B Cell Lymphoma. Blood. American Society of Hematology; 2024. p. 68–68.

Published In

Blood

DOI

EISSN

1528-0020

ISSN

0006-4971

Publication Date

November 5, 2024

Volume

144

Issue

Supplement 1

Start / End Page

68 / 68

Publisher

American Society of Hematology

Related Subject Headings

  • Immunology
  • 3213 Paediatrics
  • 3201 Cardiovascular medicine and haematology
  • 3101 Biochemistry and cell biology
  • 1114 Paediatrics and Reproductive Medicine
  • 1103 Clinical Sciences
  • 1102 Cardiorespiratory Medicine and Haematology